10-QPeriod: Q2 FY2014

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2014

Filed August 5, 2014For Securities:AMGN

Summary

Amgen Inc. reported solid revenue growth for the second quarter of 2014, with total revenues reaching $5.18 billion, an 11% increase compared to the prior year quarter. This growth was primarily driven by strong performance in product sales, particularly from newer products like Kyprolis® (acquired through Onyx Pharmaceuticals) and continued strength in established blockbusters such as Enbrel®, Prolia®, and Xgeva®. Despite increased operating expenses, largely due to acquisition-related costs including amortization of intangible assets from the Onyx acquisition, operating income saw a significant 23% increase. Net income also rose by 23% year-over-year for the quarter, signaling effective cost management and operational efficiency. The company also announced a significant restructuring plan in July 2014, involving workforce reductions and facility closures to further optimize its cost structure, which is expected to incur substantial charges but aims to drive future innovation and efficiency.

Financial Highlights

55 data points
Beta

Revenue

$5.18B

74.7% Gross Margin

Net Income

$1.55B

29.9% Net Margin

EPS (Diluted)

$2.01

Total Assets

$69.53B

Cash & Equivalents

$4.35B

Free Cash Flow

$2.05B

Financial Statements
Beta
Revenue$5.18B
Cost of Revenue$1.08B
Gross Profit$3.87B
SG&A Expenses$1.14B
Operating Expenses$3.28B
Operating Income$1.90B
Interest Expense$282.00M
Net Income$1.55B
EPS (Basic)$2.04
EPS (Diluted)$2.01
Shares Outstanding (Basic)759.00M
Shares Outstanding (Diluted)768.00M

Key Highlights

  • 1Total revenues increased by 11% to $5.18 billion in Q2 2014 compared to Q2 2013.
  • 2Product sales grew by 8% to $4.95 billion, boosted by Kyprolis®, Prolia®, and XGEVA®.
  • 3Operating income increased by a strong 23% year-over-year, reaching $1.9 billion.
  • 4Net income rose by 23% to $1.55 billion for the quarter.
  • 5Diluted Earnings Per Share (EPS) grew by 22% to $2.01.
  • 6The company announced a significant restructuring plan in July 2014, aiming to reduce staff by 2,400-2,900 and close facilities, expecting pre-tax charges of $775 million to $950 million.
  • 7Cash and cash equivalents and marketable securities significantly increased to $26.19 billion as of June 30, 2014.

Frequently Asked Questions

The primary driver of revenue growth was a significant increase in product sales, up 8% to $4.95 billion. This was fueled by strong performance from newly acquired products like Kyprolis® (following the Onyx acquisition) and continued growth from key products such as Enbrel®, Prolia®, and XGEVA®.

The acquisition of Onyx Pharmaceuticals, completed in October 2013, contributed significantly to revenue growth, particularly through the inclusion of Kyprolis®. However, it also led to increased operating expenses, including substantial non-cash amortization of acquired intangible assets related to developed product technology rights, which impacted the Cost of Sales as a percentage of product sales.

The restructuring plan, announced post-quarter end but disclosed in this filing, aims to improve Amgen's cost structure and invest in future innovation. It involves significant staff reductions (2,400-2,900 employees) and facility closures, which will result in substantial pre-tax charges ($775 million to $950 million) expected in 2014 and 2015. This indicates a strategic shift towards greater efficiency and focus on pipeline development.

Amgen's liquidity position strengthened considerably. Cash, cash equivalents, and marketable securities combined increased by approximately $6.79 billion from December 31, 2013, to $26.19 billion as of June 30, 2014. This increase was largely driven by net cash provided by operating activities and significant debt issuances.